172 related articles for article (PubMed ID: 27287519)
1. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
[TBL] [Abstract][Full Text] [Related]
2. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
Zhang L; Shi S; Antochshuk V
J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
[TBL] [Abstract][Full Text] [Related]
4. Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis.
Zhang K; Wrzosek T; Desai KG; Monck M
PDA J Pharm Sci Technol; 2020; 74(1):15-26. PubMed ID: 31519785
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.
Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006
[TBL] [Abstract][Full Text] [Related]
6. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
Werk T; Volkin DB; Mahler HC
Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
[TBL] [Abstract][Full Text] [Related]
7. Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.
Ríos Quiroz A; Lamerz J; Da Cunha T; Boillon A; Adler M; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV
Pharm Res; 2016 Feb; 33(2):450-61. PubMed ID: 26474763
[TBL] [Abstract][Full Text] [Related]
8. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.
Kalonia C; Kumru OS; Prajapati I; Mathaes R; Engert J; Zhou S; Middaugh CR; Volkin DB
J Pharm Sci; 2015 Feb; 104(2):536-47. PubMed ID: 25302696
[TBL] [Abstract][Full Text] [Related]
9. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
[TBL] [Abstract][Full Text] [Related]
10. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
[TBL] [Abstract][Full Text] [Related]
11. Measuring Subvisible Particles in Protein Formulations Using a Modified Light Obscuration Sensor with Improved Detection Capabilities.
Ríos Quiroz A; Québatte G; Stump F; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV; Adler M
Anal Chem; 2015 Jun; 87(12):6119-24. PubMed ID: 26001042
[TBL] [Abstract][Full Text] [Related]
12. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
[TBL] [Abstract][Full Text] [Related]
13. Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.
Krause N; Kuhn S; Frotscher E; Nikels F; Hawe A; Garidel P; Menzen T
AAPS J; 2021 Jan; 23(1):13. PubMed ID: 33398482
[TBL] [Abstract][Full Text] [Related]
14. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
Nishi H; Mathäs R; Fürst R; Winter G
J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
[TBL] [Abstract][Full Text] [Related]
15. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
Patel AR; Lau D; Liu J
Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
[TBL] [Abstract][Full Text] [Related]
16. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
[TBL] [Abstract][Full Text] [Related]
17. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
Nayak A; Colandene J; Bradford V; Perkins M
J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
[TBL] [Abstract][Full Text] [Related]
18. Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product.
Pardeshi NN; Qi W; Dahl K; Caplan L; Carpenter JF
J Pharm Sci; 2017 Feb; 106(2):511-520. PubMed ID: 27832839
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.
Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML
J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
